HCA Healthcare Inc

HCA Healthcare Inc(HCA)股票分析

$470.440

+9.879 (+2.10%)收盘时

Loading chart…
最高
472.390
开盘
463.090
成交量加权均价
466.88
成交量
1.08M
市值
89.91B
最低
457.800
成交额
504.91M
企业价值/息税折旧摊销前利润(TTM)
9.20

HCA Healthcare, Inc. is a health care services company. The Company provides acute care hospitals, ambulatory surgery centers (ASCs), freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, comprehensive rehabilitation and physical therapy centers, hospices, and various other facilities. Its general, acute care hospitals provide a full range of services to accommodate such medical specialties as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, as well as diagnostic and emergency services. Its behavioral hospitals provide a full range of mental health care services through inpatient, partial hospitalization and outpatient settings. It operates approximately 190 hospitals comprised of 179 general acute care hospitals, seven behavioral hospitals, and four rehabilitation hospitals and its facilities are in 19 states and the United Kingdom.

AI 分析 of HCA Healthcare Inc (HCA)

买入

HCA Healthcare Inc is a good buy right now due to its current price of $451.09 being below the analyst price target of $495, indicating a potential upside of about 9.7%. Additionally, the stock has a strong forward P/E ratio of 13.85, suggesting it is undervalued compared to its growth potential. The recent positive momentum, with a 5-day change of +5.72% and an RSI of 76.97, indicates strong buying interest, although it is approaching overbought territory. The main risk is the insider selling, which has increased by 1487.91% over the last month, indicating potential concerns about future performance.

分析师评级(22)

上行空间 +4.56%
买入
16 买入
6 持有
0 卖出
当前: 470.44
最低
420.00
平均
491.89
最高
525.00

TD Cowen

2026-10-12

目标价

$460

买入

RBC Capital

2026-10-07

目标价

$496

跑赢大盘

BMO Capital

2026-09-22

目标价

$495

跑赢大盘

JPMorgan

2026-08-20

目标价

$425

中性

BofA

2026-08-10

目标价

$425

中性

估值指标

HCA Healthcare Inc(HCA)当前预期市盈率为 13.85,5 年平均预期市盈率为 14.01。

预期市盈率

合理
5 年均值 P/E
14.01
当前P/E
13.85
高估
15.51
低估
12.52

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
9.04
当前EV/EBITDA
9.20
高估
9.63
低估
8.45

预期市销率

合理
5 年均值 P/S
1.16
当前P/S
1.22
高估
1.30
低估
1.03

Alphio AI 对 HCA 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%HCA

$444.76

情景价格

基

基准

基准 · 50%HCA

$443.49

情景价格

悲

悲观

悲观 · 25%HCA

$394.94

情景价格

持有 HCA 的大户

C

Cbus Industry Superannuation Fund

+ 持有HCA

+9.20%

3个月收益率

H

Hercules Holding Ii, LLC

+ 持有HCA

+8.68%

3个月收益率

L

LGT Fund Management Company AG

+ 持有HCA

+8.05%

3个月收益率

A

Arrowstreet Capital, Limited Partnership

+ 持有HCA

+7.99%

3个月收益率

I

INTECH Investment Management LLC

+ 持有HCA

+7.79%

3个月收益率

S

Sanders Capital, LLC

+ 持有HCA

+7.60%

3个月收益率

HCA 常见问题 —— 由 Alphio AI 解答

HCA Healthcare, Inc. is a health care services company. The Company provides acute care hospitals, ambulatory surgery centers (ASCs), freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, comprehensive rehabilitation and physical therapy centers, hospices, and various other facilities. Its general, acute care hospitals provide a full range of services to accommodate such medical specialties as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, as well as diagnostic and emergency services. Its behavioral hospitals provide a full range of mental health care services through inpatient, partial hospitalization and outpatient settings. It operates approximately 190 hospitals comprised of 179 general acute care hospitals, seven behavioral hospitals, and four rehabilitation hospitals and its facilities are in 19 states and the United Kingdom. It operates in the Healthcare sector (SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC industry).

HCA Healthcare Inc is a good buy right now due to its current price of $451.09 being below the analyst price target of $495, indicating a potential upside of about 9.7%. Additionally, the stock has a strong forward P/E ratio of 13.85, suggesting it is undervalued compared to its growth potential. The recent positive momentum, with a 5-day change of +5.72% and an RSI of 76.97, indicates strong buying interest, although it is approaching overbought territory. The main risk is the insider selling, which has increased by 1487.91% over the last month, indicating potential concerns about future performance.

22 analysts cover HCA: 16 rate it Buy, 6 Hold and 0 Sell. The average price target is 491.89.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易